Carvalho, Hugo
Verdonck, Michaël
Brull, Sorin J.
Fuchs-Buder, Thomas
Forget, Patrice
Flamée, Panagiotis
Poelaert, Jan
Funding for this research was provided by:
Agentschap Innoveren en Ondernemen (HBC.2019.2196, HBC.2019.2196, HBC.2019.2196)
Wetenschappelijk Fonds Willy Gepts (WFWG19-07, WFWG19-07, WFWG19-07)
Vrije Universiteit Brussel (Industrieel Onderzoeksfonds (IOF), Industrieel Onderzoeksfonds (IOF), Industrieel Onderzoeksfonds (IOF))
Belgian Society of Anaesthesiology Resuscitation, Perioperative Medicine and Pain Management (Unrestricted Research Grant, Unrestricted Research Grant, Unrestricted Research Grant)
Article History
Received: 14 July 2022
Revised: 24 August 2022
Accepted: 18 September 2022
First Online: 10 November 2022
Declarations
:
: SJB: Conflicts of Interest: S. J. Brull has intellectual property assigned to Mayo Clinic (Rochester, MN); has received research support (funds to Mayo Clinic) from Merck & Co, Inc (Kenilworth, NJ) and is a consultant for Merck & Co, Inc; is a principal, shareholder, and chief medical officer in Senzime AB (publ) (Uppsala, Sweden); and is a member of the scientific/ clinical advisory boards for the Doctors Company (Napa, CA), Coala Life, Inc (Irvine, CA), NMD Pharma (Aarhus, Denmark), and Takeda Pharmaceuticals (Cambridge, MA). TFB received lecture fees from MSD, France.
: The other authors did not have any conflict of interest.